Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. (KROS) is a clinical-stage biopharmaceutical company pioneering TGF-β-targeted therapies for blood, bone, and cardiovascular disorders. This page aggregates official news releases and analysis-worthy developments related to their innovative pipeline, including elritercept (KER-050) and cibotercept (KER-012).
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. The curated feed includes essential announcements about myelodysplastic syndrome treatments, pulmonary arterial hypertension research, and neuromuscular disease therapeutic advances.
Content spans trial design publications, patient enrollment updates, IND submissions, and collaborative research agreements. All materials are sourced from company filings and verified industry channels to ensure accuracy.
Bookmark this page for structured access to Keros Therapeutics' latest scientific advancements and corporate communications. Check regularly for material updates that may impact research trajectories or market positioning.
Keros Therapeutics (Nasdaq: KROS) reported its Q2 2024 financial results, showing a net loss of $45.3 million, up from $37.5 million in Q2 2023. The increase was primarily due to expanded R&D efforts and investments in clinical and corporate goals. Research and development expenses rose to $40.5 million from $32.5 million year-over-year, while general and administrative expenses increased to $10.0 million from $8.8 million. Despite the losses, Keros' cash position strengthened to $405.9 million as of June 30, 2024, up from $331.1 million at the end of 2023. The company expects this cash reserve to fund operations into 2027. Keros highlighted positive regulatory and data updates for its elritercept (KER-050) program and strong enrollment in the Phase 2 trial of cibotercept (KER-012) for pulmonary arterial hypertension.
Keros Therapeutics (Nasdaq: KROS) announced leadership changes effective July 1, 2024. Dr. Jasbir Seehra, currently CEO, will become Chair of the Board, succeeding Dr. Carl Gordon, who will remain an active Board member. Jean-Jacques Bienaimé will take over as Lead Independent Director of the Board. Additionally, Christopher Rovaldi has been promoted to President, while retaining his role as Chief Operating Officer. These changes come as Keros prepares for its first Phase 3 clinical trial of elritercept (KER-050) for lower-risk myelodysplastic syndromes. Dr. Seehra and Dr. Gordon both expressed confidence in the new leadership structure to drive the company's strategic and operational priorities.
Keros Therapeutics presented new clinical data from its ongoing Phase 2 trials of elritercept (KER-050) at the 29th Annual Hybrid Congress of the European Hematology Association. The data highlights elritercept's potential in treating lower-risk myelodysplastic syndromes (MDS) and myelofibrosis (MF). Key findings include durable transfusion independence, improved patient fatigue scores, and reductions in spleen volume. Elritercept was generally well-tolerated with no treatment-related fatalities. Keros plans to initiate a Phase 3 clinical trial in MDS following positive FDA feedback, marking a significant step towards potential commercialization.
Keros Therapeutics (Nasdaq: KROS) announced a corporate update conference call and webcast on June 17, 2024, at 8:00 a.m. Eastern time. The company received positive feedback from the FDA regarding its KER-050 (elritercept) program for myelodysplastic syndromes (MDS), aligning on the design and endpoints for the proposed Phase 3 clinical trial. CEO Jasbir S. Seehra, Ph.D., mentioned ongoing Phase 2 TROPOS trial for KER-012 (cibotercept) in pulmonary arterial hypertension (PAH), with enrollment expected to complete in Q4 this year. The webcast will be accessible via Keros’s website, with an archived version available for 90 days post-call.
Keros Therapeutics, a clinical-stage biopharmaceutical company, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference.
The event will be held on June 10, 2024, at 2:40 p.m. Eastern time. Keros' President and CEO, Jasbir S. Seehra, Ph.D., will present at a fireside chat session.
A live audio webcast of the presentation will be available, with an archived replay accessible on the Keros website for 90 days post-event.
Keros Therapeutics, a clinical-stage biopharmaceutical company, appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024.
Bienaimé brings extensive experience from his tenure as CEO and Chairman of BioMarin Pharmaceutical, Genencor, and Sangstat Medical He also held senior positions at Rhône-Poulenc Rorer Pharmaceuticals and Genentech.
Keros' CEO, Jasbir Seehra, emphasized Bienaimé's expertise in executive leadership, strategic planning, and product development, noting it will support Keros' growth and pipeline progression.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that five abstracts from its KER-050 (elritercept) program will be presented at the 29th Annual Congress of the European Hematology Association (EHA) from June 13-16, 2024. These presentations, both virtual and in-person, include findings from an ongoing Phase 2 trial in participants with lower-risk MDS, potential cardiovascular benefits, and KER-050's capacity to treat myelofibrosis and mitigate ruxolitinib-associated cytopenias. Additionally, data shows reduced ferritin levels and increased bone-specific alkaline phosphatase in lower-risk MDS participants, suggesting potential to rebalance the osteohematopoietic niche. A preclinical study demonstrated that KER-050 increased muscle mass and strength in a mouse model of myelofibrosis.
Keros Therapeutics, a clinical-stage biopharmaceutical company, reported a business update and financial results for Q1 2024. The company is focused on developing therapeutics for patients with disorders related to TGF-ß proteins. Key highlights include progress in clinical trials and upcoming milestones for 2024. Financially, Keros reported a net loss of $43.1 million for Q1 2024, attributed to increased research and development expenses. However, the company's cash reserves of $442.4 million as of March 31, 2024, are expected to fund operations until 2027.
FAQ
What is the current stock price of Keros Therapeutics (KROS)?
What is the market cap of Keros Therapeutics (KROS)?
